Back to search

Peptide record

TPDB25657

Antibacterial Antiviral Toxicity modified_plain modified
42 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25657
Antibacterial Antiviral Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A 42-aa modified multi-activity (Antibacterial, Antiviral, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGX
Physicochemical Analysis
C208H336N48O71S1
RCHPW
EL
4677.29
4.14
5
10
16
-5
16.28
-0.438
102.14
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
2980
63.71
9
Residue Composition
number
1
A
0
R
1
N
3
D
0
C
7
E
1
Q
3
G
0
H
3
I
7
L
5
K
1
M
1
F
0
P
4
S
1
T
0
W
2
Y
1
V
Amino Acid Distribution
A: 1 R: 0 N: 1 D: 3 C: 0 E: 7 Q: 1 G: 3 H: 0 I: 3 L: 7 K: 5 M: 1 F: 1 P: 0 S: 4 T: 1 W: 0 Y: 2 V: 1
Chemical Descriptors
42
C208H336N48O71S1
4677.29
4.14
-5
16.28
-0.438
Evidence Records 2 records
Evidence 1 Activity

Activity

<5% Cytotoxicity
Toxicity
10 µM
Cytotoxic
<5% Cytotoxicity | 10 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | MBio | 2020
Evidence 2 Activity

Activity

18% Cytotoxicity
Toxicity
10 µM
Cytotoxic
18% Cytotoxicity | 10 | µM | target cell: Vero E6 cells

Target

Vero E6 cells

Source & Reference

NA
DBAASP
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | MBio | 2020